MedTrace Logo

Effect of Ancestry Supplementation in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT07592013 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-18

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the effect of Ancestry, a supplement made from Mexican-origin foods (nopal, cacao, and cricket) in adults with Metabolic dysfunction-associated steatotic liver disease (MASLD). The main questions it aims to answer are:

* Does the supplementation with Ancestry improve the hepatic steatosis grade in participants with MASLD?
* Does the supplementation improve biochemical and anthropometric parameters in participants with MASLD?
* Does the supplementation enrich the abundance of beneficial bacteria in the gut microbiota of participants?

Researchers will compare the supplement group to a placebo group to see if the supplement is effective.

Participants will:

* Take the supplement or a placebo every day for 3 months.
* Receive nutritional guidance from a trained dietitian to control dietary intake.
* Attend follow-up clinic visits every month for monitoring and checkups.

Conditions

  • MASLD

Interventions

DIETARY_SUPPLEMENT

Ancestry

The active intervention consists of a daily oral supplement in powder form, containing a 30g mixture of dehydrated Mexican-origin foods: nopal (10g), cocoa powder (10g), and cricket (10g). The supplement will be consumed once daily for 3 months. Participants will be instructed to mix the entire 30g powder content with 250 ml of water and consume it immediately.

OTHER

Placebo

The placebo consists of a daily oral supplement in powder form, containing a mixture of calcium caseinate (10g) and maltodextrin (5g). This matched formulation is designed to equalize the caloric value and macronutrient profile of the active intervention. The placebo will be consumed once daily for 3 months. Participants will be instructed to mix the entire powder content with 250 ml of water and consume it immediately.

Sponsors & Collaborators

  • Instituto de Salud Digestiva y Hepatica S.A de C.V.

    collaborator OTHER

  • Instituto Tecnologico y de Estudios Superiores de Monterey

    collaborator OTHER

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Juan Armendáriz-Borunda, PhD, FAASLD · University of Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2026-10-31
Completion
2027-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07592013 on ClinicalTrials.gov